11th ASM Conference on Candida and candidiasis

说明： 念珠菌是人类的主要真菌病原体，可引起从口腔和阴道念珠菌病到危及生命的念珠菌症和侵袭性疾病等一系列疾病。念珠菌领域专注于与流行病学、耐药性、感染、宿主反应、疫苗和治疗学有关的广泛主题。念珠菌和念珠菌病会议每两年举行一次，是介绍这些不同领域的前沿进展和最新观点的主要论坛。请求提供资金，为将于2012年3月29日至4月2日在加利福尼亚州旧金山举行的第十一届念珠菌和念珠菌病会议提供部分支持。这次会议将由美国微生物学会主办，该学会将提供管理专业知识和资金支持。该计划将以该系列以往的会议为基础，可靠地吸引了450多名美国和国际科学家参加，并在参与者调查中得到了热情的支持。该计划将包括38名演讲者，他们将因其在基础和/或临床真菌学方面的专业知识而被选中，48名演讲者将根据提交的摘要进行选择。这一安排将提供灵活性，以介绍前沿进展，并招募各种新兴和成熟的社区成员作为演讲者。将有关于念珠菌病的流行病学、诊断和治疗的临床讲座，演讲者将经过仔细的亲和力和有效性筛选。这些会谈将 纳入侧重于念珠菌感染的各个关键方面的会议，包括环境信号、系统生物学、抗真菌剂和耐药性、免疫识别、疫苗、形态发生和生物被膜。将有两个午餐会，基础科学家和临床医生将讨论各种实验性念珠菌病啮齿动物模型的优缺点。此外，还将同时举行关于真菌代谢、新技术、表观遗传学和细胞凋亡的会议，以进一步鼓励富有成效的互动和讨论。每天下午，将有一个海报展示环节，总共展示250-300张海报。我们有信心我们的目标--呈现最新的 将在这一领域取得进展，突出初级科学家(特别是妇女和少数群体)的成就，促进协同作用和跨学科互动，并为社区范围的讨论提供场所。 公共卫生相关性： 念珠菌是引起传染病的主要真菌，影响艾滋病患者、癌症化疗患者、早产儿和许多其他人。第12届念珠菌和念珠菌病会议将为念珠菌研究界提供一个论坛，介绍最新的进展和想法，涵盖从临床问题到分子机制，从真菌的生长到宿主反应的广泛主题。这次会议将有助于规划未来研究的进程，促进了解、治疗和预防疾病的迫切需要。

DESCRIPTION: Candida is the major fungal pathogen of humans, causing diseases that range from oral and vaginal candidiasis to life-threatening candidemia and invasive disease. The Candida field focuses on a broad spectrum of subjects that relate to epidemiology, drug resistance, infection, host response, vaccines and therapeutics. The Candida and Candidiasis Conference, held every two years, is the premier forum for the presentation of cutting-edge advances and the latest perspectives in these diverse areas. Funds are requested to provide partial support for the 11th Conference on Candida and Candidiasis, which will be held from March 29 to April 2, 2012, in San Francisco, CA. The conference will be sponsored by the American Society for Microbiology, which will provide both management expertise and financial support. The program will be based upon past conferences of the series, which have reliably drawn attendance of over 450 American and International scientists, and have been met with enthusiastic support in participant surveys. This program will include 38 speakers who will be chosen for their expertise in fundamental and/or clinical mycology and 48 speakers who will be selected based on submitted abstracts. This arrangement will provide the flexibility to present cutting-edge advances and to enlist a diverse spectrum of emerging and established community members as speakers. There will be clinical talks about the epidemiology, diagnosis, and treatment of candidiasis, with speakers carefully prescreened for affability and effectiveness. These talks will be incorporated into sessions that focus on various key aspects of candidal infections, including environmental signaling, systems biology, antifungal agents and resistance, immune recognition, vaccines, morphogenesis, and biofilms. There will be two lunch sessions in which the strengths and weakness of various experimental rodent models of candidiasis will be discussed by both basic scientists and clinicians. In addition, there will be concurrent sessions on fungal metabolism, new technologies, epigenetics, and apoptosis to further encourage productive interaction and discussion. Each afternoon, there will be a poster session so that a total of 250-300 posters will be presented. We are confident that our goals - to present the latest advances in the field, to spotlight achievements of junior scientists (especially women and minorities), to promote synergistic and interdisciplinary interactions, and to provide a venue for community-wide discussion - will be achieved. PUBLIC HEALTH RELEVANCE: Candida is the major fungus that causes infectious disease, affecting AIDS patients, cancer chemotherapy patients, premature infants, and many others. The 12th Conference on Candida and Candidiasis will provide a forum for the Candida research community to present the most recent advances and ideas, covering a broad spectrum of subjects from clinical issues to molecular mechanisms, from growth of the fungus to response of the host. The conference will help chart the course of future research and facilitate the urgent necessity to understand, treat, and prevent disease.